NI200700094A - Métodos para la neuroprotección - Google Patents

Métodos para la neuroprotección

Info

Publication number
NI200700094A
NI200700094A NI200700094A NI200700094A NI200700094A NI 200700094 A NI200700094 A NI 200700094A NI 200700094 A NI200700094 A NI 200700094A NI 200700094 A NI200700094 A NI 200700094A NI 200700094 A NI200700094 A NI 200700094A
Authority
NI
Nicaragua
Prior art keywords
formula
group
phenyl
alkyl
methods
Prior art date
Application number
NI200700094A
Other languages
English (en)
Inventor
Roy E Twyman
Boyu Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI200700094A publication Critical patent/NI200700094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Ésta invención está dirigida a métodos para proveer neuroprotección que comprende la administración a un sujeto en necesidad de los mismos una cantidad terapéuticamente efectiva de un compuesto seleccionado del grupo que compone la Fórmula (I) y Fórmula (II), o una sal o éster farmacéuticamente aceptable de los mismos,: Fórmula (I), Fórmula (II) en donde el fenilo es sustituido en X con de uno a cinco átomos de halógeno seleccionados del grupo que consiste en flúor, cloro, bromo y yodo; y, R1, R2, R3, R4, R5 y R6 son seleccionados independientemente del grupo que consiste en hidrógeno y alquilo C1-C4; en donde el alquilo C1-C4 es sustituido opcionalmente con fenilo ( en donde el fenilo es sustituido opcionalmente con sustituyentes seleccionados independientemente del grupo que consiste en halógeno, alquilo C1-C4, alcoxi C1-C4, amino, nitro y ciano).
NI200700094A 2004-10-15 2005-10-14 Métodos para la neuroprotección NI200700094A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61940204P 2004-10-15 2004-10-15
US69840305P 2005-07-12 2005-07-12

Publications (1)

Publication Number Publication Date
NI200700094A true NI200700094A (es) 2008-02-11

Family

ID=35840528

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700094A NI200700094A (es) 2004-10-15 2005-10-14 Métodos para la neuroprotección

Country Status (14)

Country Link
EP (1) EP1802294A1 (es)
JP (1) JP2008516961A (es)
KR (3) KR20110049901A (es)
AU (1) AU2005295787A1 (es)
BR (1) BRPI0516112A (es)
CA (1) CA2584854A1 (es)
EA (1) EA200700871A1 (es)
EC (1) ECSP077395A (es)
IL (1) IL182432A0 (es)
MX (1) MX2007004491A (es)
NI (1) NI200700094A (es)
NO (1) NO20072444L (es)
SG (1) SG142306A1 (es)
WO (1) WO2006044472A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CN115996905A (zh) 2020-08-31 2023-04-21 生物药品解决方案有限公司 用于预防或治疗神经退行性疾病的氨基甲酸苯基烷基酯化合物
BR112023004354A2 (pt) 2020-09-10 2023-04-04 Bio Pharm Solutions Co Ltd Compostos derivados de sulfamato para uso no tratamento ou alívio de um transtorno psiquiátrico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
SK286621B6 (sk) * 1999-08-20 2009-02-05 Ortho-Mcneil Pharmaceutical, Inc. Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva
CA2439295C (en) * 2001-02-27 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neurodegenerative disorders
KR20070057939A (ko) * 2004-09-16 2007-06-07 얀센 파마슈티카 엔.브이. 간질형성 및 간질을 치료하는 방법

Also Published As

Publication number Publication date
JP2008516961A (ja) 2008-05-22
IL182432A0 (en) 2007-09-20
BRPI0516112A (pt) 2008-08-26
KR20070085309A (ko) 2007-08-27
EA200700871A1 (ru) 2007-10-26
WO2006044472A1 (en) 2006-04-27
MX2007004491A (es) 2007-08-08
AU2005295787A1 (en) 2006-04-27
EP1802294A1 (en) 2007-07-04
CA2584854A1 (en) 2006-04-27
NO20072444L (no) 2007-06-14
SG142306A1 (en) 2008-05-28
KR20110049901A (ko) 2011-05-12
ECSP077395A (es) 2007-05-30
KR20090130175A (ko) 2009-12-18

Similar Documents

Publication Publication Date Title
NI200800008A (es) Métodos para la neuroprotección
CO6180427A2 (es) Tratamiento de los trastornos generalizados del desarrollo
AR054524A1 (es) Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato
ECSP088172A (es) Metodos para tratar la epileptogenesis
NO20071921L (no) Fremgangsmater for behandling av epileptogenese og epilepsi
NI200700094A (es) Métodos para la neuroprotección
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
EA200800422A1 (ru) Способы лечения заболеваний, обусловленных химическими веществами
AR052885A1 (es) Metodos para el control del intervalo qt
AR083180A1 (es) Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa
CO6180505A2 (es) Metodos para el tratamiento de transtornos cocleares y vestibulares
AR033426A1 (es) Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento
IL157590A0 (en) Carbamate compounds for use in preventing or treating bipolar disorder
CO6160292A2 (es) Metodos de tratamiento de transtornos de comportamiento perturbador 877
AR077884A1 (es) (4-(5-aminometil- fenil)-piperidin-1-il)-1h-indol-3-il)-metanonas disustituidas
SE0401578D0 (sv) Novel compounds
AR035757A1 (es) Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar
UY29158A1 (es) Metodos de tratamiento de la epileptogénesis y la epilepsia
PE20060559A1 (es) Compuestos derivados de carbamato para el tratamiento de trastornos relacionados con sustancias
CR9766A (es) Metodos para el tratamiento de trastornos relacionados con sustancias
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
AR032907A1 (es) Uso de compuestos carbamatos para la prevencion o tratamiento de trastornos de ansiedad